Locations:
Search IconSearch
September 21, 2021/Cancer/Radiation Oncology

Research Proves Feasibility of New Cancer Treatment Approach

Radiation planning technique safely reduces toxicity

RTOG_690-x-380-650×358

Researchers from Cleveland Clinic and OhioHealth have published results from a first-in-human trial evaluating feasibility of Temporally Feathered Radiation Therapy (TFRT), which is designed to reduce the toxicity of radiation treatment.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The research, appearing in Radiotherapy & Oncology, proved TFRT’s feasibility in clinical workflow. Additionally, assessments of treatment toxicities and radiation dosage comparisons to a standard radiotherapy plan were described.

TFRT is a novel technique for the planning and optimization of radiotherapy that considers the nonlinear aspects of normal tissue repair to manage toxicity. The technique is designed to reduce radiation-induced toxicities by optimizing the time through which radiation is delivered and consequently improves normal tissue recovery. Radiation-induced toxicity is a major contributor to impacting a patients’ quality of life and often a dose-limiting factor in the treatment of cancer with radiation therapy.

“We are excited that the complex TFRT technique, which uses current planning systems, was able to be delivered safely and in a standard clinical workflow,” said Jacob G. Scott, M.D., DPhil, a Cleveland Clinic radiation oncologist and the inventor of TFRT. “A larger trial with toxicity as the primary endpoint will allow us to truly study the efficacy of the approach. Collaboration will be important as we work to integrate TFRT into planning systems to expand automation and wider adoption into clinical practice.”

Study specifics

In this study, five patients with head and neck squamous cell carcinoma were treated with TFRT. The primary endpoint was feasibility of TFRT planning as defined by radiation start within 15 days of treatment planning. Secondary endpoints included estimates of toxicity.

Advertisement

The primary endpoint was met when patients were successfully treated with TFRT techniques without causing delays in radiation commencement. For patients who received TFRT, the median time from treatment planning to radiation start was 10 business days – not outside of standard timelines. The average time required for radiation planning was six days. The organs feathered included oral cavity, each submandibular gland, each parotid gland, supraglottis, and posterior pharyngeal wall. There were no significant deviations from standard planning, and toxicity was no more than expected – but we expect a larger trial to show reductions in toxicity without effecting cure rates.

“Radiation oncologists and physicists have made amazing advances in shaping the radiation dose to organs and tissue near a patient’s tumors, leading to effective treatments with less toxicity,” added Shireen Parsai, M.D., a radiation oncologist at OhioHealth who led this research during her residency at Cleveland Clinic. “TFRT takes advantage of the differential repair of tumors vs. healthy tissue by modulating how the dose is delivered to nearby tissue over time. This approach gives normal tissue more time to heal, allowing us, in theory, to deliver the same curative doses of radiation with less detriment to the patient’s quality of life.”

Advertisement

Related Articles

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Woman consoling another
June 5, 2026/Cancer/Blood Cancers

Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma

Research underscores the importance of access to timely diagnosis and treatment in this patient population.

Multiple myeloma cells
June 4, 2026/Cancer/Blood Cancers

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma

A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.

Dr. Kamath & colleagues in the lab
June 2, 2026/Cancer/News & Insight

Tissue Tumor Mutation Burden Outperforms Blood-Based Testing for Predicting Immunotherapy Response

Study serves as ‘cautionary tale’ for physicians tempted to rely on liquid biopsy results alone

Patient with nebulizer
June 1, 2026/Cancer/Innovations

Adding Novel Inhaled Agent May Improve Lung Cancer Outcomes

Direct delivery of viral-based vector KB707 to the lungs may boost anti-tumor response and help overcome immune checkpoint inhibitor resistance

Ad